Faeth Therapeutics, Inc. (FTH)
19.39
+0.59
(+3.14%)
USD |
NASDAQ |
Oct 19, 16:00
19.39
0.00 (0.00%)
After-Hours: 16:21
Faeth Therapeutics Enterprise Value : 306.58M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 306.58M |
| October 15, 2026 | 353.08M |
| October 14, 2026 | 337.58M |
| October 13, 2026 | 376.59M |
| October 12, 2026 | 421.54M |
| October 09, 2026 | 493.35M |
| October 08, 2026 | 482.50M |
| October 07, 2026 | 464.68M |
| October 06, 2026 | 515.57M |
| October 05, 2026 | 520.99M |
| October 02, 2026 | 553.28M |
| October 01, 2026 | 551.22M |
| September 30, 2026 | 589.19M |
| September 29, 2026 | 546.05M |
| September 28, 2026 | 538.30M |
| September 25, 2026 | 544.24M |
| September 24, 2026 | 571.37M |
| September 23, 2026 | 635.95M |
| September 22, 2026 | 683.74M |
| September 21, 2026 | 680.90M |
| September 18, 2026 | 712.16M |
| September 17, 2026 | 728.43M |
| September 16, 2026 | 705.44M |
| September 15, 2026 | 734.63M |
| September 14, 2026 | 830.73M |
| Date | Value |
|---|---|
| September 11, 2026 | 788.11M |
| September 10, 2026 | 828.40M |
| September 09, 2026 | 754.01M |
| September 08, 2026 | 833.57M |
| September 04, 2026 | 855.53M |
| September 03, 2026 | 828.40M |
| September 02, 2026 | 831.50M |
| September 01, 2026 | 712.41M |
| August 31, 2026 | 667.47M |
| August 28, 2026 | 695.11M |
| August 27, 2026 | 692.52M |
| August 26, 2026 | 672.63M |
| August 25, 2026 | 712.67M |
| August 24, 2026 | 717.58M |
| August 21, 2026 | 647.57M |
| August 20, 2026 | 650.16M |
| August 19, 2026 | 676.25M |
| August 18, 2026 | 673.41M |
| August 17, 2026 | 667.47M |
| August 14, 2026 | 656.36M |
| August 13, 2026 | 558.45M |
| August 12, 2026 | 579.89M |
| August 11, 2026 | 595.91M |
| August 10, 2026 | 558.97M |
| August 07, 2026 | 450.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Opus Genetics, Inc. | 264.76M |
| Nuvectis Pharma, Inc. | 474.36M |
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.01M |
| Total Expenses (Quarterly) | 16.01M |
| EPS Diluted (Quarterly) | -2.836 |
| Earnings Yield | -730.5% |
| Normalized Earnings Yield | -335.64 |